Past performance does not predict future results. Informational only, not investment advice.
Femasys received FDA approval for a modular PMA pathway for FemBloc, its non-surgical permanent birth control technology. The company is positioned for a potential rally with resistance at 3.48 from a current price of 2.65.
Nantahala Capital Partners Limited Partnership disclosed a 9.99% stake of 803,038 shares in FEMASYS INC. (FEMY) in a Schedule 13D filed 2026-08-17.
Femasys secured FDA approval to advance the final FemBloc trial phase with $12M in immediate financing and potential $58M total from convertible notes and warrants. The C-1 warrants exercisable at $1.10 establish a structural support level, combined with surging volume and decreasing shares available to short suggesting potential squeeze dynamics.
FEMY holds exclusive, non-surgical contraceptive technology and IVF-enhancement products with compelling market potential. At $27M market cap, the stock is undervalued relative to its $3.40 IPO price and analyst targets of $6–$8, offering significant upside on an upcoming 11/6 earnings announcement.
Femasys' FemBloc is a first-in-class non-surgical permanent birth control device with strong revenue potential if it captures even 1% of the addressable market (~$150M annually), supported by insurance coverage incentives and European partnerships. Phase 3 trial completion in April 2027 could unlock significant upside for this micro-cap biotech.
Femasys has secured CE Mark approval for FemBloc, its first non-surgical permanent birth control system, with early European orders and U.S. FDA trials underway. Multiple near-term catalysts (revenue updates, European launches, clinical readouts) combined with recent $8M financing and Russell Microcap inclusion position this microcap for potential significant upside as products reach market.
End of results.